氨磺必利联合奥氮平治疗精神分裂症的临床研究

Clinical Study of Amisulpride Combined with Olanzapine in the Treatment of Schizophrenia

目的探析对精神分裂症患者行以氨磺必利联合奥氮平治疗的临床效果。方法选取2018年5月—2019年2月该院收治的88例精神分裂症患者,根据治疗方案差异将其分成两组,对照组44例患者行以奥氮平治疗,研究组44例患者行以氨磺必利联合奥氮平治疗,对照分析两组疗效。结果从临床总有效率上来看,研究组(86.36%)高于对照组(63.64%)(P<0.05);从PANSS评分上来看,治疗前组间差异无统计学意义(P>0.05),治疗后研究组一般病理评分、阳性症状评分、阴性症状评分、总分分别为(33.79±3.11)分、(15.33±2.27)分、(14.20±2.67)分、(63.33±2.45)分,各项指标均低于对照组(t=3.361、3.081、2.878、12.036,P=0.001、0.003、0.005、0.000<0.05);从不良反应上来看,研究组发生率(12.50%)低于对照组(65.91%)(χ^2=20.566,P=0.000<0.05)。结论对精神分裂症患者来说,氨磺必利联合奥氮平治疗可取得良好效果,可以使患者精神症状得到改善,且安全性良好,具有显著临床价值。

Objective To analyze the clinical effect of amisulpride combined with olanzapine in patients with schizophrenia.Methods From May 2018 to February 2019,88 patients with schizophrenia were selected from the hospital.They were divided into two groups according to the difference of treatment options.44 patients in the control group were treated with olanzapine,and 44 patients in the study group were treated with amisulpride combined with olanzapine,and the effects of the two groups were compared.Results From the perspective of clinical total effective rate,the study group(86.36%)was higher than the control group(63.64%)(P<0.05).From the PANSS score,there was no statistical difference between the groups before treatment(P>0.05),and the general pathology of the study group after treatment,positive symptom scores,negative symptom scores,and total scores were(33.79±3.11)points,(15.33±2.27)points,(14.20±2.67)points,and(63.33±2.45)points,respectively(t=3.361,3.081,2.878,12.036,P=0.001,0.003,0.005,0.000<0.05;from the adverse reaction,the incidence of the study group(12.50%)was lower than that of the control group(65.91%)(χ^2=20.566,P=0.000<0.05).Conclusion For patients with schizophrenia,amisulpride combined with olanzapine can achieve good results,can improve the patient's mental symptoms,and has good safety and significant clinical value.